Given the heterogeneous preliminary results so far in trials applying IL-6 blockade in more severe cases of COVID-19 [22, 23], the results of the present study may suggest to elucidate the specific role of IL-6 blockade in uncomplicated COVID-19 patients with cardiovascular comorbidities. This evidence concerns the gene IL6 and COVID-19.